Adze-1.17.C.4.P-35 / Adze Biotech - LARVOL DELTA

Adze Biotechnology Granted Patent for its Proprietary Oncolytic Adenovirus Platform (EIN Presswire) - "Adze Biotechnology Granted Patent for its Proprietary Oncolytic Adenovirus Platform. Adze Biotechnology, Inc...announced that it has received a patent grant to an embodiment of its proprietary oncolytic adenovirus platform. The patent includes claims to the oncolytic adenovirus comprising a plurality of PD-1 polypeptides on the surface of the virus and the methods of treating cancer with the same....Adze plans to begin clinical trials in 2023 in melanoma in using Adze systemically deliverable oncolytic immunotherapies. Additionally, clinical trials in prostate cancer are being planned for 2024."

New trial • Patent • Genito-urinary Cancer • Melanoma • Oncology • Prostate Cancer • Skin Cancer